ML-007
Experimental muscarinic drug
From Wikipedia, the free encyclopedia
ML-007 is a selective muscarinic acetylcholine M1 and M4 receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias.[1][2][3][4][5][6] It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC).[2][5][4] The drug is taken orally.[1]
| Clinical data | |
|---|---|
| Other names | ML007; ML-007/PAC; ML007/PAC |
| Routes of administration | Oral[1] |
| Drug class | Muscarinic acetylcholine M1 and M4 receptor agonist[1] |
It produces antipsychotic-like effects in rodents, including inhibition of amphetamine and phencyclidine (PCP)-induced hyperlocomotion and activity in the conditioned avoidance response test.[6] These effects appear to dependent on activation of both muscarinic acetylcholine M1 and M4 receptors.[6] The drug is approximately 10-fold more potent than xanomeline in these tests.[6]
As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias.[1][3][4] It is under development by MapLight Therapeutics.[1][3] The drug is a small molecule, but its chemical structure does not seem to have been disclosed.[5][1][3]